toll free: 1800 3070 6727 Email Id: email@example.com
All Ovarian cancer patients
Approved by US FDA
BRCA positive patients can benefit with PARP inhibitors
Testing BRCA gene mutation on Tumor helps identify 50% more patients eligible for treatment with PARP inhibitors
Sample Requirement: FFPE Blocks or Blood
Illumina Next Generation Sequencing
CAP & CLIA certified laboratory
Reporting time: 3 weeks
Download sample report
BRACAnalysis CDx is an FDA-approved companion diagnostic test for BRCA1 and BRCA2
intended to be used as an aid in treatment decision making for olaparib, a PARP inhibitor
BRACAnalysis CDx is the first and only FDA-approved laboratory developed test (LDT)
that indicates whether or not a patient with ovarian cancer may be eligible for treatment with the PARP inhibitor Olaparib.
With the introduction of PARP inhibitors, BRCA mutation testing is critical in
ovarian cancer patients to identify the subset of women who might benefit from this therapy choice.
BRCA testing can be done on blood, saliva or tumour. BRACAnalysisCDX is done
on tumour. Testing the tumor rather than blood or saliva for the mutation identifies 50% more patients with :
A BRCA1 or BRCA2 mutation
Helps more ovarian cancer patients understand their treatment options
Identifies 50% more patients with BRCA-mutated ovarian cancer compared
to testing via blood or saliva
My mother had ovarian cancer. After taking cisplatin we were looking for a therapy to maintain her response. We underwent BRACAnalysisCDX which was positive in her case and we started giving her Olaparib.
Better understand a patients’ risk for specific health conditions
Prescribe more suitable medications at optimal dosages for patients, as needed.
Suggest early lifestyle and diet interventions to help control or prevent certain health conditions.
Best treatment recommendation
Provides information on pathway analysis
Includes Positive Bioscience expert comments and complementary consulation with your docto
65% increase in median overall survival
Multiple technology platform to provide most comprehensive recommendations
31% more accurate in identifying cancer driver mutations
Better treatment recommendation
Complementary consultation with your doctor
533, Kalbadevi Road,
Mumbai – 400002